Kura Oncology Financials
| KURA Stock | USD 7.27 0.07 0.95% |
Kura |
Please note, the presentation of Kura Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kura Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kura Oncology's management manipulating its earnings.
Kura Oncology Stock Summary
Kura Oncology competes with Protagonist Therapeutics, Merus BV, Replimune, Kalvista Pharmaceuticals, and Crinetics Pharmaceuticals. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US50127T1097 |
| CUSIP | 50127T109 |
| Location | California; U.S.A |
| Business Address | 12730 High Bluff |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | kuraoncology.com |
| Phone | 858 500 8800 |
| Currency | USD - US Dollar |
Kura Oncology Key Financial Ratios
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 | ||||
| Target Price | 26.69 | ||||
| Number Of Employees | 192 | ||||
| Beta | 0.84 |
Kura Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kura Oncology's current stock value. Our valuation model uses many indicators to compare Kura Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kura Oncology competition to find correlations between indicators driving Kura Oncology's intrinsic value. More Info.Kura Oncology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kura Oncology's earnings, one of the primary drivers of an investment's value.Kura Oncology Systematic Risk
Kura Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kura Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Kura Oncology correlated with the market. If Beta is less than 0 Kura Oncology generally moves in the opposite direction as compared to the market. If Kura Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kura Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kura Oncology is generally in the same direction as the market. If Beta > 1 Kura Oncology moves generally in the same direction as, but more than the movement of the benchmark.
About Kura Oncology Financials
What exactly are Kura Oncology Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Kura Oncology's income statement, its balance sheet, and the statement of cash flows. Potential Kura Oncology investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Kura Oncology investors may use each financial statement separately, they are all related. The changes in Kura Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kura Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Kura Oncology March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kura Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kura Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kura Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Kura Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kura Oncology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 13.72 | |||
| Value At Risk | (5.12) | |||
| Potential Upside | 4.48 |
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |